Turning Point Therapeutics (TPTX) Stock Highlights

76.01 | +0%

2022-12-24 15:31:04

Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The companys lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.

Statistics

Range Today

76.01 76.01

Volume Today 0

Range 1 Year

23.77 81.78

Volume 1 Year 217.22M

Range 3 Year

23.77 141.3

Volume 3 Year 418.16M

Range 10 Year

23.77 141.3

Volume 10 Year 440.83M

Highlights

Market Capitalization 3.81B (mid)

Current Price 76.01

Performance

Latest 0%

1 Month +1.33%

3 Months +1.78%

6 Months +200.32%

1 Year -4.39%

3 Years +76.07%

5 Years +213.44%

10 Years +213.44%

Benchmarks

Market Capitalization

48 / 368

Gross Profits

73 / 278

Total Revenue

0 / 300

Total Rank

362 / 368

Free Cashflow

0 / 352

Performance 5 years

41 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.